Etanercept biosimilar - Hanwha Chemical

Drug Profile

Etanercept biosimilar - Hanwha Chemical

Alternative Names: Davictrel; HD 203; MK-8953

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator Hanwha Chemical
  • Class Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Registered Ankylosing spondylitis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Nov 2013 Hanwha Chemical completes enrolment in the phase I EAGLE-I-13 trial in Healthy volunteers in South Korea (NCT01894412)
  • 03 Jul 2013 Hanwha Chemical initiates enrolment in the phase I EAGLE-I-13 trial in Healthy volunteers in South Korea (NCT01894412)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top